EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

Xianxian Huang, Jing Liu, Guangquan Peng, Mingyue Lu, Zhongbo Zhou, Neng Jiang iD, Zhiming Yan

Journal of Endocrinology · 2024

DOI: 10.1530/joe-23-0404 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Endocrinology, 2024. Verfasst von Xianxian Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 123 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapidly rising incidence of obesity, coupled with type 2 diabetes mellitus (T2DM), is a growing concern. Glucagon-like peptide 1 (GLP-1), an endogenous peptide secreted by enteroendocrine L-cells, demonstrates exceptional pharmacological potential for the treatment of T2DM and obesity, primarily through its pivotal roles in regulating glucose homeostasis, stimulating glucose-dependent insulin secretion, and promoting satiety. Considering its proven efficacy in glucoregulation and weight loss, GLP-1 receptor agonists (GLP-1RAs) have emerged as a revolutionary breakthrough in the arena of diabetes management and weight control. Additional gastrointestinal hormones, such as glucose-dependent insulinotropic peptide (GIP) and glucagon, exhibit structural similarities to GLP-1 and work synergistically to lower blood glucose levels or aid in weight loss. Today, various classes of gut hormone receptor multiple agonists are steadily progressing through development and clinical trials, including dual GLP-1/glucagon receptor agonists (first discovered in 2009), dual GLP-1/GIP receptor agonists (first described in 2013), and triple GLP-1/GIP/glucagon receptor agonists (initially designed in 2015). The GLP-1/GIP receptor co-agonist, tirzepatide, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of T2DM, outperforming basal insulin or selective GLP-1RAs by providing superior HbA1c reductions. Remarkably, tirzepatide also facilitated unprecedented weight loss of up to 22.5% in non-diabetic individuals living with obesity. This result is comparable to those achieved with certain types of bariatric surgery. Therefore, the advent of gut hormone multi-agonists signifies the dawn of an exciting new era in peptide-based therapy for obesity and T2DM. This review offers a comprehensive summary of the various types of gut hormone multiple agonists, including their discovery, development, action of mechanisms, and clinical effectiveness. We further delve into potential hurdles, limitations, and prospective advancements in the field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2ObesityHumansGastrointestinal HormonesHypoglycemic AgentsGlucagon-Like Peptide 1AnimalsGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

gut hormone multi-agonistsobesitypeptidestype 2 diabetes

Substanzen

Gastrointestinal HormonesHypoglycemic AgentsGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Pharmaceutical College, Guangxi Medical University, Nanning, Guangxi, China.
  • School of Pharmacy, Youjiang Medical University for Nationalities, Baise, Guangxi, China.

ORCID-Profile: Neng Jiang

Zitieren

APA

Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024). Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges. Journal of Endocrinology. https://doi.org/10.1530/joe-23-0404

Vancouver

Huang X, Liu J, Peng G, Lu M, Zhou Z, Jiang N, et al. Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges. Journal of Endocrinology. 2024. doi:10.1530/joe-23-0404

BibTeX
@article{Huang2024,
  author = {Huang, Xianxian and Liu, Jing and Peng, Guangquan and Lu, Mingyue and Zhou, Zhongbo and Jiang, Neng and Yan, Zhiming},
  title = {Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges},
  journal = {Journal of Endocrinology},
  year = {2024},
  doi = {10.1530/joe-23-0404}
}
Kostenlos starten →